CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM signed deal

Greifswald, 13/10/2021

This week Cheplapharm agreed with Sanofi on an asset-deal of 10 established products. The portfolio consists of three corticosteroids, one topic antibiotic and one combination of topic antibiotic and corticosteroid. It is distributed in more than 15 countries, including  Egypt, Mexico and France. The closing of the transaction is scheduled for the first quarter 2022. 

The APIs of the referring products are Prednisolone (as NA Methylsulpho Benzoate, NA Phosphate and Acetate), Deflazacort, Prednisone, Framycetin Sulfate (and also in combination with Gramicidin and Dexamethasone). The registered brand names of the products in this portfolio are Deflazacort®/Calcort®/Flantadin®, Otodex®/Soframycin®, Sofradex®/Sofracort®, Hydrocortancyl®, Solupred® and Cortancyl®/Prednisona®. The product name varies depending on the country in which it is marketed.

The transaction includes product registrations, intellectual property, certain contracts and inventory. The deal does not include any transfer of manufacturing facilites or employees.


Investor Relations topics

Back to top expand_less